The global nuclear medicine market is expected to reach $9.4 billion by 2028, growing at a CAGR of 11.3% during the forecast period. The diagnostic segment, including SPECT and PET, accounted for the largest share in 2022. North America currently has the largest market share, but Asia Pacific is expected to witness the fastest growth. Key drivers of the market include the growing prevalence of chronic diseases and the demand for personalized medicine. However, there are constraints on the widespread adoption of nuclear medicine, such as the short half-life of radiopharmaceuticals and the limited availability of radioisotopes. Emerging trends and technologies in nuclear medicine include theranostics, molecular imaging, hybrid imaging, alpha-emitting radionuclides, targeted radionuclide therapy, radiomics, artificial intelligence, and efforts to enhance the production and availability of radiopharmaceuticals. These advancements hold promise for improving patient outcomes and expanding the applications of nuclear medicine.
Thu, 13 Jul 2023 04:01:42 GMT | Med Device Online